KMDA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

45.81M

+16.05%

0.077

+10.71%

43.98M

-0.28%

0.070

51.30M

+13.44%

0.100

-23.08%

Estimates Revision

The market is revising Downward the revenue expectations for Kamada Ltd. (KMDA) for FY2025, with the revenue forecasts being adjusted by -0.62% over the past three months. During the same period, the stock price has changed by 3.13%.

Revenue Estimates for FY2025

Revise Downward

-0.62%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-4.58%

In Past 3 Month

Stock Price

Go Up

+3.13%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast KMDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KMDA is 11.00 USD with a low forecast of 11.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 7.250

Low

11.00

Averages

11.00

High

11.00

Current: 7.250

Low

11.00

Averages

11.00

High

11.00

H.C. Wainwright

Buy

maintain

$11 -> $13

2025-12-09

Reason

H.C. Wainwright

Price Target

$11 -> $13

2025-12-09

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Kamada to $13 from $11 and keeps a Buy rating on the shares. The company decided to discontinue its Phase 3 inhaled alpha-1 antitrypsin deficiency clinical trial based on the results of the planned interim futility analysis, the analyst tells investors in a research note. The firm says the decision helps to refocus the company on its core products and eliminates a "long over-hanging distraction that was unlikely to be fruitful."

Benchmark

Robert Wasserman

Strong Buy

Initiates

$15

2025-03-21

Reason

Benchmark

Robert Wasserman

Price Target

$15

2025-03-21

Initiates

Strong Buy

Reason

Benchmark analyst Robert Wasserman initiated coverage of Kamada with a Buy rating and $15 price target.

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$11

2025-03-06

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$11

2025-03-06

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$11

2025-01-10

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$11

2025-01-10

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Kamada Ltd (KMDA.O) is 19.18, compared to its 5-year average forward P/E of 4.05. For a more detailed relative valuation and DCF analysis to assess Kamada Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

4.05

Current PE

19.18

Overvalued PE

12.53

Undervalued PE

-4.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

5.59

Current EV/EBITDA

6.71

Overvalued EV/EBITDA

10.69

Undervalued EV/EBITDA

0.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.10

Current PS

2.11

Overvalued PS

2.70

Undervalued PS

1.51

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

KMDA News & Events

Events Timeline

No data

News

9.0

12-08Benzinga

Kamada Halts Phase 3 Trial for Genetic Disorder, Reaffirms Future Projections

2.0

12-08Globenewswire

Kamada Discontinues AAT Trial After Futility Analysis, Reiterates 2025 Revenue Guidance of $178M-$182M

3.0

11-07SeekingAlpha

Kamada's Earnings Outlook for Q3 2025

People Also Watch

Frequently Asked Questions

What is Kamada Ltd (KMDA) stock price today?

The current price of KMDA is 7.25 USD — it has increased 3.28 % in the last trading day.

What is Kamada Ltd (KMDA)'s business?

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

What is the price predicton of KMDA Stock?

What is Kamada Ltd (KMDA)'s revenue for the last quarter?

Kamada Ltd revenue for the last quarter amounts to 47.01M USD, increased 12.63 % YoY.

What is Kamada Ltd (KMDA)'s earnings per share (EPS) for the last quarter?

Kamada Ltd. EPS for the last quarter amounts to 0.09 USD, increased 28.57 % YoY.

What changes have occurred in the market's expectations for Kamada Ltd (KMDA)'s fundamentals?

How many employees does Kamada Ltd (KMDA). have?

Kamada Ltd (KMDA) has 374 emplpoyees as of December 16 2025.

What is Kamada Ltd (KMDA) market cap?

Today KMDA has the market capitalization of 418.19M USD.